CTLA4expressing

CTLA-4 expressing refers to cells that display the CTLA-4 protein on their surface or within intracellular compartments. CTLA-4, or cytotoxic T-lymphocyte-associated protein 4, is an immune checkpoint receptor in the CD28 family that modulates T cell activation and tolerance. Expression is tightly regulated and varies with cell type and activation state.

In humans, CTLA-4 expression is low or undetectable on naïve T cells but becomes upregulated after T cell activation. It is constitutively expressed at high levels on regulatory T cells (Tregs), where it contributes to their suppressive function. Some activated CD8+ T cells and certain B cells can also express CTLA-4, though the levels and duration of expression are generally less stable than on Tregs. CTLA-4 is primarily localized intracellularly in resting cells and traffics to the cell surface upon activation, with rapid internalization that helps limit sustained signaling.

Functionally, CTLA-4 serves as a negative regulator of T cell responses. It competes with the costimulatory receptor CD28 for binding to the ligands CD80 and CD86 on antigen-presenting cells, and it delivers inhibitory signals through intracellular pathways. A notable mechanism is trans-endocytosis, whereby CTLA-4 removes CD80/CD86 from APCs, reducing subsequent costimulation. This activity helps maintain peripheral tolerance and prevents autoimmunity.

Clinically, CTLA-4 expression and function have therapeutic relevance. CTLA-4–Ig fusion proteins (abatacept, belatacept) block costimulation to dampen immune responses in autoimmune disease and transplantation. Conversely, anti–CTLA-4 antibodies (such as ipilimumab) block CTLA-4 to enhance anti-tumor immunity. The level and context of CTLA-4 expression can influence responses to these therapies and may serve as a biomarker in research settings.